Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PAXIS: A Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Study (Part 1) Followed by an Open-label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome

Next Previous
Trial Profile

PAXIS: A Randomized, Double-blind, Placebo-controlled Dose-finding Phase 2 Study (Part 1) Followed by an Open-label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients With VEXAS Syndrome

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacritinib (Primary)
  • Indications Myelofibrosis; VEXAS syndrome
  • Focus Therapeutic Use
  • Acronyms PAXIS
  • Sponsors Swedish Orphan Biovitrum

Most Recent Events

  • 10 Dec 2025 Status changed from recruiting to active, no longer recruiting.
  • 25 Oct 2025 According to Sobi North America media release, data from this trial presented at the annual American College of Rheumatology (ACR) Convergence 2025 meeting
  • 25 Oct 2025 Results published in the Sobi North America Media Release

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top